PTN - Palatin Technologies, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
0.4184
+0.0015 (+0.36%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.4169
Open0.4300
Bid0.3971 x 1000
Ask0.4100 x 800
Day's Range0.3900 - 0.4300
52 Week Range0.3600 - 1.7800
Volume772,435
Avg. Volume1,562,138
Market Cap95.914M
Beta (5Y Monthly)1.67
PE Ratio (TTM)2.72
EPS (TTM)0.1540
Earnings DateFeb 10, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.17
  • Does Palatin Technologies, Inc.'s (NYSEMKT:PTN) CEO Salary Compare Well With Others?
    Simply Wall St.

    Does Palatin Technologies, Inc.'s (NYSEMKT:PTN) CEO Salary Compare Well With Others?

    In 2000 Carl Spana was appointed CEO of Palatin Technologies, Inc. (NYSEMKT:PTN). This report will, first, examine the...

  • Analysts: These 3 “Strong Buy” Penny Stocks Could Gain Over 200%
    TipRanks

    Analysts: These 3 “Strong Buy” Penny Stocks Could Gain Over 200%

    Buying a single share of tech giant Google will set you back a not inconsiderable $1386.32. Accordingly, you get to own a piece of one of the world’s most successful companies, with a proven business model and the likely scenario of further gains in the long run. But how much gains, really? With a market cap of almost $1 trillion, the search engine behemoth can grow further but the incredible returns are probably over by now.On the opposite end of the scale are the puny, unloved penny stocks (anything going for less than 3 bucks). The potential for multiple gains becomes more likely, but let’s not forget that along with the higher chance of mercurial returns, comes the significant risk of losing all your hard-earned cash on a very risky investment. It’s not for nothing, that some on Wall Street believe backing penny stocks is more akin to gambling than proper investing.For those still set on following the risk tolerant path, the next step is to identify the right names to provide those sky-scraping returns. This is where the pros come in handy.With the help of TipRanks’ Stock Screener tool, we identified three penny stocks which some on the Street see potential for upside of at least 200%. In addition, all currently have a Strong Buy consensus rating attached to their names. Let’s take a look at why analysts find these stocks such compelling buys right now.Palatin Technologies (PTN)Let’s start off with the “penniest” of the lot. Palatin's stock is trading at $0.48 each, following a decline of nearly 40% year-to-date. Some on the Street, though, believe now is the time to snap up shares of the Cranbury, New Jersey based microcap.Palatin develops peptide therapeutics for diseases with significant unmet medical needs. The company’s varied pipeline includes candidates for the treatment of heart failure, diabetes and inflammatory diseases.Taking most of the headlines is Palatin’s lead product Vyleesi (Bremelanotide), a treatment for hypoactive sexual desire disorder (HSDD). Vyleesi was approved by the FDA in June 2019, and its North American rights are currently exclusively licensed to AMAG Pharmaceuticals. However, due to an internal shake up, AMAG decided recently to divest Vylessi and is currently in the search for a new US home for the drug. Palatin management believes that a new partnership should be in place in the next few months.Cannacord’s John Newman is backing the company to find a new suitable US partner for the drug while also increasing its international presence. The 5-star analyst said, “Palatin expects to announce additional executed partnerships for Vyleesi in all worldwide geographic areas outside North America by the end of 2020. We continue to expect a robust new partner for Vyleesi near-term and await details in March on the AMAG call. We believe Vyleesi will be competitively differentiated vs. Addyi, which must be given chronically and has potentially dangerous interaction with alcohol.”Newman, therefore, keeps his Buy rating as is, but the analyst’s price target is reduced from $4 to $3. Nevertheless, the upside potential still comes in at a moon landing 512%. (To watch Newman’s track record, click here)Out on the Street, two other analysts are currently backing Newman’s arguments in Palatin’s favor. The additional Buy ratings add up to a Strong Buy consensus rating, along with an average price target of $2.17. The intrepid investor could be pocketing a 339% gain should the analysts’ thesis play out. (See Palatin price targets and analyst ratings on TipRanks)TherapeuticsMD (TXMD)Further up the market cap ladder we find TherapeuticsMD, a pharmaceutical company exclusively committed to advancing women’s health. The small-cap’s stock, which is going for $1.63 per share, has suffered so far in 2020, losing 33% of its value.The company has several products on the market; these include BIJUVA, which is used for the relief of moderate to severe hot flashes due to menopause, and IMVEXXY, a vaginal estrogen therapy used to treat moderate to severe vaginal pain associated with sexual activity.Cowen’s Ken Cacciatore, though, reserves the bulk of his positive summery of TXMD, for Annovera, a birth control vaginal ring. The drug is a combined hormonal contraceptive and is the first vaginal ring contraceptive that can be used for an entire year. Annovera was approved by the FDA in August 2018 and notched sales of $5.8 million in 4Q19.Cacciatore argues the contraceptive “is the most underappreciated component of the story, as it is unique & differentiated.”The analyst noted, “Q4 rev reached $16MM, allowing access to another $50MM under its credit agreement. And encouragingly, given Annovera's early trends, management guided 2020 revenue to $90-110MM. This is increasingly becoming an Annovera story, and given our consultants views, we believe the Street might not yet appreciate its potential. As Annovera gains traction, we believe that the operational turn is nearing.”Accordingly, Cacciatore reiterated an Outperform rating on TXMD, along with a $9 price target. This implies upside of a massive 445%. (To watch Cacciatore’s track record, click here)While the last three months have seen only two further analysts throwing the hat in with a view on TherapeuticsMD’s prospects, both are even more bullish than the Cowen analyst. A Strong Buy consensus rating comes with an average price target of $10.67, indicating the analysts’ belief that an extra 549% will be added to the share price in the next 12 months. (See TXMD stock analysis on TipRanks)Rigel (RIGL)The final cheap stock on our list is Rigel, a pharma company developing novel small molecule drugs. Shares of Rigel are selling for $2.16 a piece, and at least one Wall Street pro sees this as a buying opportunity.Apart from ongoing development for a number of candidates, Rigl has one FDA approved product out on the shelves -- Tavalisse (fostamatinib disodium hexahydrate). Tavalisse is a tablet which is used for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Currently, the drug is the only oral spleen tyrosine kinase (SYK) inhibitor used to treat the disease.Sales of Tavalisse have been growing. Rigel’s latest quarterly report showed that US Tavalisse sales increased quarter-over-quarter by 18% to $13.8 million.With that said, Piper Sandler’s Christopher Raymond remains Overweight on RIGL. The 5-star analyst’s rating is accompanied by an $8 price target, which implies potential upside of an impressive 270% from current levels. (To watch Raymond’s track record, click here)The analyst notes that in the last quarter, Tavalisse’s 4-month refill rate was 54%. This indicates that physicians are increasingly comfortable with the treatment. Raymond added further, “We believe this will continue to serve as a nice touchpoint with physicians and will watch for additional adoption in earlier lines of therapy throughout 2020, with supportive data expected from ongoing case series and investigator-sponsored research in addition to initiation of an observational study in 2L ITP patients this year. As for Europe, following EU approval announced in January, partner Grifols plans to launch product in Q220, with incremental revenue from EU sales expected in 2H20.”All in all, 4 unanimous Buy ratings for Rigel coalesce into a Strong Buy consensus rating. the average price target comes in at $7.25 and implies possible upside of 234%. (See Rigel stock analysis on TipRanks)

  • Introducing Palatin Technologies (NYSEMKT:PTN), A Stock That Climbed 69% In The Last Three Years
    Simply Wall St.

    Introducing Palatin Technologies (NYSEMKT:PTN), A Stock That Climbed 69% In The Last Three Years

    While Palatin Technologies, Inc. (NYSEMKT:PTN) shareholders are probably generally happy, the stock hasn't had...

  • Palatin Technologies, Inc. Announces First Patient Enrolled in Dry Eye Disease Phase 2 Clinical Trial with PL9643
    PR Newswire

    Palatin Technologies, Inc. Announces First Patient Enrolled in Dry Eye Disease Phase 2 Clinical Trial with PL9643

    Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today announced that it has enrolled the first patient in a Phase 2 clinical trial of topical PL9643, a melanocortin 1/5 receptor (MC1/5r) agonist, for the treatment of dry eye disease (DED).

  • Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2020 Financial Results and Recent Business Highlights
    PR Newswire

    Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2020 Financial Results and Recent Business Highlights

    Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, whose product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its second quarter ended December 31, 2019.

  • Palatin Technologies, Inc. to Report Second Quarter Fiscal Year 2020 Results; Teleconference and Webcast to be held on February 11, 2020
    PR Newswire

    Palatin Technologies, Inc. to Report Second Quarter Fiscal Year 2020 Results; Teleconference and Webcast to be held on February 11, 2020

    Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter fiscal year 2020 operating results on Tuesday, February 11, 2020 before the open of the U.S. financial markets.

  • Palatin Provides Corporate Update and 2020 Calendar Outlook
    PR Newswire

    Palatin Provides Corporate Update and 2020 Calendar Outlook

    Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today provided a corporate update and outlook for calendar year 2020.

  • Should We Be Delighted With Palatin Technologies, Inc.'s (NYSEMKT:PTN) ROE Of 38%?
    Simply Wall St.

    Should We Be Delighted With Palatin Technologies, Inc.'s (NYSEMKT:PTN) ROE Of 38%?

    Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...

  • Is Palatin Technologies, Inc. (PTN) Going To Burn These Hedge Funds ?
    Insider Monkey

    Is Palatin Technologies, Inc. (PTN) Going To Burn These Hedge Funds ?

    Hedge funds are not perfect. They have their bad picks just like everyone else. Facebook, a stock hedge funds have loved dearly, lost nearly 40% of its value at one point in 2018. Although hedge funds are not perfect, their consensus picks do deliver solid returns, however. Our data show the top 20 S&P 500 […]

  • Is Palatin Technologies, Inc. (NYSEMKT:PTN) A Volatile Stock?
    Simply Wall St.

    Is Palatin Technologies, Inc. (NYSEMKT:PTN) A Volatile Stock?

    Anyone researching Palatin Technologies, Inc. (NYSEMKT:PTN) might want to consider the historical volatility of the...

  • Thomson Reuters StreetEvents

    Edited Transcript of PTN earnings conference call or presentation 13-Nov-19 4:00pm GMT

    Q1 2020 Palatin Technologies Inc Earnings Call

  • Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2020 Results and Provides Corporate Update
    PR Newswire

    Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2020 Results and Provides Corporate Update

    Vyleesi™ launched nationally in September Teleconference and Webcast to be held on November 13, 2019 CRANBURY, N.J. , Nov. 13, 2019 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized ...

  • Palatin Technologies, Inc. to Report First Quarter Fiscal Year 2020 Results; Teleconference and Webcast to be held on November 13, 2019
    PR Newswire

    Palatin Technologies, Inc. to Report First Quarter Fiscal Year 2020 Results; Teleconference and Webcast to be held on November 13, 2019

    CRANBURY, N.J. , Nov. 7, 2019 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter fiscal year 2020 operating results on Wednesday, November 13, 2019 before the ...

  • Does Palatin Technologies (NYSEMKT:PTN) Deserve A Spot On Your Watchlist?
    Simply Wall St.

    Does Palatin Technologies (NYSEMKT:PTN) Deserve A Spot On Your Watchlist?

    For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

  • Palatin Presents On Pl8177 Oral Colon Delivery Formulation For Ulcerative Colitis At The 7Th CPC Symposium On Peptide Therapeutics
    PR Newswire

    Palatin Presents On Pl8177 Oral Colon Delivery Formulation For Ulcerative Colitis At The 7Th CPC Symposium On Peptide Therapeutics

    CRANBURY, N.J., Oct. 17, 2019 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) announced that John Dodd, Ph.D., Palatin's Vice President of Pre-Clinical Development, provided a presentation on Palatin's oral colon delivery formulation, PL8177 in development for the treatment of ulcerative colitis, at the 7th CPC Symposium on Peptide Therapeutics in Hangzhou, China.

  • Vyleesi™ Phase 3 Data To Be Presented At The 13th European Society Of Gynecology Congress
    PR Newswire

    Vyleesi™ Phase 3 Data To Be Presented At The 13th European Society Of Gynecology Congress

    CRANBURY, N.J. , Oct. 16, 2019 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) announced today that data from two pivotal, double-blind placebo-controlled Phase 3 trials (RECONNECT) and ...

  • How Many Palatin Technologies, Inc. (NYSEMKT:PTN) Shares Do Institutions Own?
    Simply Wall St.

    How Many Palatin Technologies, Inc. (NYSEMKT:PTN) Shares Do Institutions Own?

    The big shareholder groups in Palatin Technologies, Inc. (NYSEMKT:PTN) have power over the company. Institutions will...

  • Thomson Reuters StreetEvents

    Edited Transcript of PTN earnings conference call or presentation 12-Sep-19 3:00pm GMT

    Q4 2019 Palatin Technologies Inc Earnings Call

  • Should You Consider Palatin Technologies, Inc. (NYSEMKT:PTN)?
    Simply Wall St.

    Should You Consider Palatin Technologies, Inc. (NYSEMKT:PTN)?

    Building up an investment case requires looking at a stock holistically. Today I've chosen to put the spotlight on...

  • Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year 2019 Results
    PR Newswire

    Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year 2019 Results

    Teleconference and Webcast to be held on September 12, 2019 CRANBURY, N.J. , Sept. 12, 2019 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing ...

  • Palatin Technologies, Inc. to Report Fourth Quarter & Fiscal Year End 2019 Results; Teleconference and Webcast to be held on September 12, 2019
    PR Newswire

    Palatin Technologies, Inc. to Report Fourth Quarter & Fiscal Year End 2019 Results; Teleconference and Webcast to be held on September 12, 2019

    CRANBURY, N.J. , Sept. 11, 2019 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2019 operating results on Thursday, September 12, 2019 ...

  • Can You Imagine How Palatin Technologies's (NYSEMKT:PTN) Shareholders Feel About The 80% Share Price Increase?
    Simply Wall St.

    Can You Imagine How Palatin Technologies's (NYSEMKT:PTN) Shareholders Feel About The 80% Share Price Increase?

    Palatin Technologies, Inc. (NYSEMKT:PTN) shareholders might understandably be very concerned that the share price has...

  • Palatin's (PTN) to Report Q4 Earnings: What's in the Cards?
    Zacks

    Palatin's (PTN) to Report Q4 Earnings: What's in the Cards?

    Investors will focus on pipeline updates, when Palatin (PTN) releases fourth-quarter fiscal 2019 results.

  • Palatin (PTN) Stock Sinks As Market Gains: What You Should Know
    Zacks

    Palatin (PTN) Stock Sinks As Market Gains: What You Should Know

    In the latest trading session, Palatin (PTN) closed at $0.91, marking a -1.7% move from the previous day.

  • Is Palatin Technologies (PTN) Outperforming Other Medical Stocks This Year?
    Zacks

    Is Palatin Technologies (PTN) Outperforming Other Medical Stocks This Year?

    Is (PTN) Outperforming Other Medical Stocks This Year?